{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:31:21Z","timestamp":1791228681868,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T00:00:00Z","timestamp":1451952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Chemoimmunotherapy followed by autologous stem cell transplantation (<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>) is a standard therapy for transplant\u2010eligible patients with newly diagnosed mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>). The achievement of complete remission (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>) and minimal residual disease (<jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content>) negativity are associated with better outcomes. We tested an induction regimen of rituximab\/bendamustine followed by rituximab\/high\u2010dose cytarabine (<jats:styled-content style=\"fixed-case\">RB<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RC<\/jats:styled-content>). This phase 2 study (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>01661881) enrolled 23 transplant\u2010eligible patients aged 42\u201369, of whom 70% were <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content> international prognostic index low\u2010risk. Patients received three cycles of <jats:styled-content style=\"fixed-case\">RB<\/jats:styled-content> followed by three cycles of <jats:styled-content style=\"fixed-case\">RC<\/jats:styled-content>. The primary endpoint of the trial was the rate of <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> after six cycles of therapy, with a rate of 75% considered promising. 96% of patients achieved a <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>\/unconfirmed <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> after treatment, meeting the primary objective. One patient progressed on study, one declined <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>, and the remaining 21 underwent successful stem cell collection and <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>. After a median follow\u2010up of 13\u00a0months, the progression\u2010free survival rate was 96%. Among 15 <jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content><jats:bold>\u2010<\/jats:bold>evaluable patients who completed treatment, 93% achieved <jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content> negativity after <jats:styled-content style=\"fixed-case\">RB<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RC<\/jats:styled-content>. In conclusion, <jats:styled-content style=\"fixed-case\">RB<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RC<\/jats:styled-content> achieves very high <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content> negativity rates in transplant\u2010eligible patients, with a favourable safety profile. <jats:styled-content style=\"fixed-case\">RB<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">RC<\/jats:styled-content> warrants further comparative studies, and may become a useful alternative to <jats:styled-content style=\"fixed-case\">RCHOP<\/jats:styled-content> (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)\u2010based induction regimens in this patient population.<\/jats:p>","DOI":"10.1111\/bjh.13929","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T14:16:21Z","timestamp":1452003381000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["A phase 2 study of Rituximab\u2010Bendamustine and Rituximab\u2010Cytarabine for transplant\u2010eligible patients with mantle cell lymphoma"],"prefix":"10.1111","volume":"173","author":[{"given":"Philippe","family":"Armand","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Redd","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Bsat","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeetha","family":"Mayuram","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Giardino","sequence":"additional","affiliation":[{"name":"Department of Radiology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Weng","sequence":"additional","affiliation":[{"name":"Sequenta Inc South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Sequenta Inc South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Faham","sequence":"additional","affiliation":[{"name":"Sequenta Inc South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold S.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Joyce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Beth Israel\u2010Deaconess Medical Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12439"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_8_6_1","first-page":"581","article-title":"RCHOP and RDHAP Followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase ii study from the GELA","volume":"112","author":"Delarue R.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444042"},{"key":"e_1_2_8_10_1","first-page":"582","article-title":"Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma","volume":"120","author":"Faham M.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2454"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-429811"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"e_1_2_8_14_1","first-page":"110","article-title":"Alternating courses of 3x CHOP and 3x DHAP Plus rituximab followed by a high dose ARA\u2010C containing myeloablative regimen and autologous stem cell transplantation (ASCT) Is Superior to 6 Courses CHOP Plus rituximab followed by myeloablative radiochemotherapy and ASCT In mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)","volume":"116","author":"Hermine O.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635169"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.375"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.050203"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.52"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13349"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-230250"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08228.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70106-3"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184200"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801923725"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2011.09.007"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9842"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13929","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:26:29Z","timestamp":1696325189000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/bjh.13929"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13929","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,5]]},"assertion":[{"value":"2015-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}